Dong-A Socio Holdings chalked up its best-ever third quarter sales in the third quarter, thanks to the listing of its major subsidiaries this year.
In a public notice released on Nov. 1, Dong-A Socio Holdings posted 356.9 billion won in consolidated sales for Q3.
The figure represents a 23.4 percent jump over the same period of last year. It is the best-ever sales since the company shifted into a holding company scheme in 2013. Dong-A Socio Holdings has renewed for the sixth consecutive quarter since the second quarter of 2023.
Dong-A Socio Holdings saw its Q3 operating profit decline 9 percent to 22.5 billion won over the same period of 2023, influenced by rising unit prices.
Dong-A Pharmaceutical saw sales surge thanks to quantitative growth of its Baccus and OTC businesses. In particular, the rising sales were led by “Noscana,” “Acnon” and “Melatoning” – skin treatment preparations in the OTC business sector, which saw sales surge by a wide margin.
The company saw its Q3 operating profit decline due to the rising unit price rate and increasing sales management costs.
Dong-A Pharmaceutical saw Q3 sales surge 4 percent year-on-year to 179.5 billion won but Q3 operating profit drop 13.8 percent year-on-year to 22.1 billion won.
Estin Bio, specializing in CMO, jumped 190.4 percent year-on-year to 16.8 billion won, thanks to rising commercialized amounts of Stelara, a biosimilar making preparations for global sales.
The company has established a global CMO business foundation by obtaining a go-ahead on Current Good Manufacturing Practice (cGMP) from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Estin Bio saw its operating profit shift from losses and profit.
Dong-A Scio Holdings saw sales surge 18.9 percent year-on-year to 986.3 billion won in the first nine months of this year, but operating profit decline 0.8 percent year-on-year to 60.4 billion won.
Dong-A Pharmaceutical saw sales increase 7.5 percent year-on-year to 513.5 billion won in the January-September period, but operating profit decline 5.1 percent year-on-year to 62.5 billion won in the first nine months of the year.
Dong-A Pharmaceutical Participates in FAPA Congress in Seoul to Promote Products
Dong-A Pharmaceutical was participating in the 2024 FAPA Congress (FAPA 2024), the pharmaceutical company said on Oct. 30.
The Federation of Asian Pharmaceutical Associations FAPA) was founded in 1964 as an international non-profit organization with its headquarters currently based in Metro Manila, Philippines.
Approximately 1,000 people form 24 countries were expected to attend FAPA 2024, to be held in COEX in Samseong-dong, Seoul, from Oct. 29until Nov. 2.
Dong-A Pharmaceutical was participating in the event as a major partner. The pharmaceutical company plans to set up a booth and promote its mainstay products.
Spectators are given the chance to look at Dong-A Pharmaceutical’s representative household medicines, such as Panpyrin, Benachio and Champ; skin treatment preparations like “Noscana Gel and Acnon,” kids products, such as “D-Panbug Gel” and “Benachio Kiz”; the Derma cosmetic brand “Fation,” “ILO” healthy functional brand; and Baccus and “Gum Guard” non-medicine brands.
An image view of “Vita Gran Vitamin C Popping Stick Shine Muscat, released by Dong-A Pharmaceutical.
Dong-A Pharmaceutical Releases ‘Vita Gran Vitamin C Popping Stick Shine Muscat’
Dong-A Pharmaceutical launched “Vita Gran Vitamin C Popping Stick Shine Muscat,” the pharmaceutical company said on Oct. 22.
The new product is a powered healthy functional food, bringing taste of Shine Muscat, a grape variety, and joy of popping candy.
Vita Gran Vitamin C Popping Stick Shine Muscat contains 300 gram of Vitamin C, necessary for protecting cells from harmful oxygen molecules called free radicals through antioxdation. It also has Vitamin B2, Vitamin D and manganic substance for integrated health care.
_동아쏘시오홀딩스 대표 정재훈.jpg)
_동아쏘시오도표_대지 1.jpg)
_비타그란 비타민C 팝핑스틱 샤인머스캣 맛.jpg)
